JAKi Regulatory Decisions - FDA, EMA, Canada Save
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
Body
Oral Surveillance study resulted in a new FDA drug safety bulleting 9/21/21 and since the label for all JAK inhibitors has changed (FDA, Canada) or will change (EMA).
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.